NCT02477917View on ClinicalTrials.gov

A Multicenter, Open Trial With Subcutaneous Immunotherapy (SCIT) in Patients With Rhinoconjunctivitis Sensitized to Parietaria Judaica

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions

Rhinoconjunctivitis

Interventions

BIOLOGICAL

Allergovac depot with Parietaria judaica pollen extract

Subcutaneous immunotherapy in depot presentation in a rapid dose escalation scheme: 6 weekly dose increasing injections at the initiation phase plus 3 maintenance monthly injections

Trial Locations (4)

46026

Hospital Universitario y Politécnico La Fe, Valencia

46520

Hosptal de Sagunto, Sagunto

03314

Hospital Vega Baja, Orihuela

Unknown

Hospital de Manises, Manises

All Listed Sponsors

lead

Roxall Medicina España S.A

INDUSTRY

NCT02477917 - A Multicenter, Open Trial With Subcutaneous Immunotherapy (SCIT) in Patients With Rhinoconjunctivitis Sensitized to Parietaria Judaica | Biotech Hunter | Biotech Hunter